GT Biopharma Inc. Common Stock (NASDAQ:GTBP)

Real-time price: | Most recent change:0.00%

GT Biopharma Inc. is an immuno-oncology company. It discovers, develops and commercializes drugs of therapeutic molecules for the treatment of cancer, myeloma, osteolytic lesions and other unmet medical needs. GT Biopharma Inc., formerly known as OXIS International Inc., is based in Tampa, Florida....

+See More


Here we provide our AYA proprietary alpha stock signals for all premium members on our AYA fintech network platform. Specifically, a high Fama-French multi-factor dynamic conditional alpha suggests that the stock is likely to consistently outperform the broader stock market benchmarks such as S&P 500, Dow Jones, Nasdaq, Russell 3000, MSCI USA, and MSCI World etc. Since March 2023, our proprietary alpha stock signals retain U.S. Patent and Trademark Office (USPTO) fintech patent protection, approval, and accreditation for 20 years. Our homepage and blog articles provide more details on this proprietary alpha stock market investment model with robust long-term historical backtest evidence.

Sharpe-Lintner-Black CAPM alpha (Premium Members Only) Fama-French (1993) 3-factor alpha (Premium Members Only) Fama-French-Carhart 4-factor alpha (Premium Members Only) Fama-French (2015) 5-factor alpha (Premium Members Only) Fama-French-Carhart 6-factor alpha (Premium Members Only) Dynamic conditional 6-factor alpha (Premium Members Only) Last update: Saturday 26 September 2026

Blog+More

Government intervention remains a major influence over global trade, finance, and technology.

Amy Hamilton

2023-08-31 10:22:00 Thursday ET

Government intervention remains a major influence over global trade, finance, and technology.

Government intervention remains a major influence over global trade, finance, and technology. Nowadays, many governments tend to eschew common ownership

+See More

Fed Chair Jerome Powell answers CBS News 60 Minutes questions about the recent U.S. economic outlook.

Dan Rochefort

2019-03-29 12:28:00 Friday ET

Fed Chair Jerome Powell answers CBS News 60 Minutes questions about the recent U.S. economic outlook.

Federal Reserve Chair Jerome Powell answers CBS News 60 Minutes questions about the recent U.S. economic outlook and interest rate cycle. Powell views the c

+See More

Addendum on empirical tests of multi-factor models for asset return prediction

Rose Prince

2022-03-05 09:27:00 Saturday ET

Addendum on empirical tests of multi-factor models for asset return prediction

Addendum on empirical tests of multi-factor models for asset return prediction Fama and French (2015) propose an empirical five-factor asset pricing mode

+See More

David Solomon succeeds Lloyd Blankfein as the new CEO of Goldman Sachs.

Fiona Sydney

2018-03-09 08:33:00 Friday ET

David Solomon succeeds Lloyd Blankfein as the new CEO of Goldman Sachs.

David Solomon succeeds Lloyd Blankfein as the new CEO of Goldman Sachs. Unlike his predecessors Lloyd Blankfein and Gary Cohn, Solomon has been an investmen

+See More

The Economist Intelligence Unit (EIU) continues to track major business risks in light of volatile stock markets.

Fiona Sydney

2019-01-11 10:33:00 Friday ET

The Economist Intelligence Unit (EIU) continues to track major business risks in light of volatile stock markets.

The Economist Intelligence Unit (EIU) continues to track major business risks in light of volatile stock markets, elections, and geopolitics. EIU monitors g

+See More

Would you rather receive $1,000 each day for one month or a magic penny that doubles each day over the same month?

Laura Hermes

2017-04-07 15:34:00 Friday ET

Would you rather receive $1,000 each day for one month or a magic penny that doubles each day over the same month?

Would you rather receive $1,000 each day for one month or a magic penny that doubles each day over the same month? At first glance, this counterintuitive

+See More